Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Above averageWe are the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes. We classify our products into three product categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Our Radiopharmaceutical Oncology product helps healthcare professionals (“HCPs”) Find, Fight and Follow cancer.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Business segments
Jun 2026 · $439.0MThe company’s own SEC segment disclosure.
- PYLARIFY$240.4M55%
- Cardiology$88.3M20%
- Neuraceq$39.6M9%
- Neurology$39.6M9%
- Strategic Partnerships And Other$19.9M5%
- License and Royalty$11.2M3%
Lantheus Holdings, Inc. (LNTH) reported revenue of $377M in Q1 2026 (quarter ended Mar 31, 2026), up 1.2% from the same quarter a year earlier. That came with a gross margin of 61% and net income of $118M (31% of revenue). For the full year FY2025, revenue was $1.54B (+0.5% year on year) and net income $234M. Its largest product in Jun 2026 was PYLARIFY at $240M, 55% of the disclosed total, well ahead of Cardiology at 20%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.
Drug Manufacturers - Specialty & Generic
Ranks #7 of 29 by Smart Score